Project Grant HT94252410281
Award Date
5/15/24
Completion Date
5/14/26
Dollars Obligated
$516K
Federal Agency
Defense Health Agency
Awardee
Mainehealth (MAYKB1LWD5U9)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Portland, ME 04101, USA
Similar Awards
This Project Grant award, valued at $750,000.00, was issued on May 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the University of Houston System to investigate "Circulating Immune Complexes as Biomarkers for Early Detection and Monitoring of Ovarian Cancer." The research aims to transform healthcare for military service members, veterans, and the broader public through innovative...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
The federal Project Grant award of $1,004,472.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research by Yale University to develop mast cell therapy for ovarian cancer. The award, which runs from June 15, 2025 to June 14, 2029, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research at Yale University is focused on innovative...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $1,297,718 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the identification of proteomic profiles and biological networks of early stage ovarian cancer from May 1, 2021 to April 30, 2025. Through this research, the grantee aims to transform healthcare for service members and the public by investigating medical solutions for the battlefield and...
This federal Project Grant award of $954,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by the Massachusetts Institute of Technology (MIT) to develop tumor-targeted nanocarriers for effective immunomodulation of ovarian cancer. The award, which runs from May 1, 2025 to April 30, 2028, will enable MIT to conduct advanced biomedical research aimed at transforming healthcare for military service members,...
The Massachusetts General Hospital will receive $408,816 under a two-year Project Grant award from the Defense Health Agency to support research on structural biology-informed optimization of antibody-drug conjugates for ovarian cancer. The goal is to minimize toxicity through this work. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care. The...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
This federal Project Grant award of $2,200,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public, with a specific focus on investigating the efficacy of tranexamic acid to reduce capillary leak, tissue edema, and fluid resuscitation requirements after severe burn injury. The award was...
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...
This federal Project Grant award, totaling $1,005,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public, with a focus on innovative research addressing critical health challenges. The award was granted to Yale University, a prestigious private research institution, to conduct research...